Paclitaxel is used for treating tumors, breast cancer, lung cancer, and pancreatic cancer. It was first introduced by Hq Specialty Pharma Corp in its drug Taxol on Dec 29, 1992. Other drugs containing Paclitaxel are Paclitaxel, Abraxane. 21 different companies have introduced drugs containing Paclitaxel.

Paclitaxel Patents

Given below is the list of patents protecting Paclitaxel, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Abraxane	US9511046 (Pediatric)	Methods of treating pancreatic cancer	Jul 12, 2034	Bristol-myers
Abraxane	US9511046	Methods of treating pancreatic cancer	Jan 12, 2034	Bristol-myers
Abraxane	US9393318 (Pediatric)	Methods of treating cancer	Sep 04, 2032	Bristol-myers
Abraxane	US9597409 (Pediatric)	Methods of treating cancer	Sep 04, 2032	Bristol-myers
Abraxane	US9393318	Methods of treating cancer	Mar 04, 2032	Bristol-myers
Abraxane	US9597409	Methods of treating cancer	Mar 04, 2032	Bristol-myers
Abraxane	US8034375 (Pediatric)	Combinations and modes of administration of therapeutic agents and combination therapy	Feb 13, 2027	Bristol-myers
Abraxane	US7758891 (Pediatric)	Combinations and modes of administration of therapeutic agents and combination therapy	Aug 21, 2026	Bristol-myers
Abraxane	US8268348 (Pediatric)	Combinations and modes of administration of therapeutic agents and combination therapy	Aug 21, 2026	Bristol-myers
Abraxane	US9101543 (Pediatric)	Combinations and modes of administration of therapeutic agents and combination therapy	Aug 21, 2026	Bristol-myers
Abraxane	US8034375	Combinations and modes of administration of therapeutic agents and combination therapy	Aug 13, 2026	Bristol-myers
Abraxane	US7758891	Combinations and modes of administration of therapeutic agents and combination therapy	Feb 21, 2026	Bristol-myers
Abraxane	US8268348	Combinations and modes of administration of therapeutic agents and combination therapy	Feb 21, 2026	Bristol-myers
Abraxane	US9101543	Combinations and modes of administration of therapeutic agents and combination therapy	Feb 21, 2026	Bristol-myers
Abraxane	US7820788 (Pediatric)	Compositions and methods of delivery of pharmacological agents	Apr 27, 2025 (Expired)	Bristol-myers
Abraxane	US7820788	Compositions and methods of delivery of pharmacological agents	Oct 27, 2024 (Expired)	Bristol-myers
Abraxane	US7923536 (Pediatric)	Compositions and methods of delivery of pharmacological agents	Jun 09, 2024 (Expired)	Bristol-myers
Abraxane	US8138229 (Pediatric)	Compositions and methods of delivery of pharmacological agents	Jun 09, 2024 (Expired)	Bristol-myers
Abraxane	US8314156 (Pediatric)	Compositions and methods of delivery of pharmacological agents	Jun 09, 2024 (Expired)	Bristol-myers
Abraxane	US7923536	Compositions and methods of delivery of pharmacological agents	Dec 09, 2023 (Expired)	Bristol-myers
Abraxane	US8138229	Compositions and methods of delivery of pharmacological agents	Dec 09, 2023 (Expired)	Bristol-myers
Abraxane	US8314156	Compositions and methods of delivery of pharmacological agents	Dec 09, 2023 (Expired)	Bristol-myers
Abraxane	US8853260 (Pediatric)	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof	Apr 10, 2021 (Expired)	Bristol-myers
Abraxane	US8853260	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof	Oct 10, 2020 (Expired)	Bristol-myers
Abraxane	USRE41884	Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions	Aug 14, 2016 (Expired)	Bristol-myers
Abraxane	US5498421	Composition useful for in vivo delivery of biologics and methods employing same	Mar 12, 2013 (Expired)	Bristol-myers
Abraxane	US5439686	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor	Feb 22, 2013 (Expired)	Bristol-myers
Abraxane	US6096331	Methods and compositions useful for administration of chemotherapeutic agents	Feb 22, 2013 (Expired)	Bristol-myers
Abraxane	US6506405	Methods and formulations of cremophor-free taxanes	Feb 22, 2013 (Expired)	Bristol-myers
Abraxane	US6537579	Compositions and methods for administration of pharmacologically active compounds	Feb 22, 2013 (Expired)	Bristol-myers
Abraxane	US6749868	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof	Feb 22, 2013 (Expired)	Bristol-myers
Abraxane	US6753006	Paclitaxel-containing formulations	Feb 22, 2013 (Expired)	Bristol-myers

Add above patents to watchlist

Paclitaxel's Family Patents

Full family tree

Paclitaxel Generic API Manufacturers

Several generic applications have been filed for Paclitaxel. The first generic version for Paclitaxel was by Teva Pharmaceuticals Usa and was approved on Jan 25, 2002. And the latest generic version is by Hainan Shuangcheng Pharmaceuticals Co Ltd and was approved on May 15, 2025.

Given below is the list of companies who have filed for Paclitaxel generic, along with the locations of their manufacturing plants worldwide.